Cargando…

PSUN123 Increased Expression of Insulin Signaling Intermediates After Six-Months Of Medical Care In Women With Obesity And Polycystic Ovary Syndrome

BACKGROUND: Recently an androgen-induced obesity-independent mechanism of insulin resistance in a mouse model mimicking lean polycystic ovary syndrome (PCOS) was discovered. To date there is little to no data on the mechanism of insulin resistance or molecular insulin signaling in adipose tissue of...

Descripción completa

Detalles Bibliográficos
Autores principales: Akalestou, Elina, Andrisse, Stanley, Johnson, Brett, Miras, Alexander Dimitri, O’Donnell, Karen, Samarasinghe, Suhaniya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624999/
http://dx.doi.org/10.1210/jendso/bvac150.050
_version_ 1784822378780426240
author Akalestou, Elina
Andrisse, Stanley
Johnson, Brett
Miras, Alexander Dimitri
O’Donnell, Karen
Samarasinghe, Suhaniya
author_facet Akalestou, Elina
Andrisse, Stanley
Johnson, Brett
Miras, Alexander Dimitri
O’Donnell, Karen
Samarasinghe, Suhaniya
author_sort Akalestou, Elina
collection PubMed
description BACKGROUND: Recently an androgen-induced obesity-independent mechanism of insulin resistance in a mouse model mimicking lean polycystic ovary syndrome (PCOS) was discovered. To date there is little to no data on the mechanism of insulin resistance or molecular insulin signaling in adipose tissue of women with PCOS undergoing Vertical Sleeve Gastrectomy (VSG). Does the mechanism of androgen receptor (AR)-mediated regulation of insulin signaling seen in the lean PCOS mouse model occur in adipose tissue of women with obesity and PCOS? OBJECTIVE: We hypothesize that in women with obesity and PCOS, those with higher levels of free androgen index will display more dysregulation in the insulin signaling pathway in adipose tissue. More specifically, we believe that visceral more than subcutaneous adipose tissue in the women in the study will display more dysregulation; and lastly that VSG will alleviate insulin signaling dysregulation. Briefly, insulin activates insulin receptor (IR) which leads to activation of phospho-AKT which increases phosphorylated forkhead box 01 (p-FOXO1, gluconeogenesis regulation) and transcriptionally regulates acetyl co-A carboxylase (ACC, de novo lipogenesis (DNL) regulation). METHODS: This is a nested mechanistic study within a randomised controlled clinical trial. We performed molecular analyses (Western blots for protein and qPRC for mRNA expression, respectively, n = 3-4/group) exploring intermediates in the insulin signaling pathway (IR, p-AKT, p-FOXO1, and ACC) in (i) visceral and subcutaneous (SubQ) adipose tissue from women with obesity and PCOS before VSG bariatric surgery (n = 3/group); and (ii) SubQ WAT from women with obesity and PCOS at baseline and six-months after medical intervention with metformin (MTF) and lifestyle modification. RESULTS: Subcutaneous (SubQ) white adipose tissue (WAT) displayed similar levels of p-ACC compared to visceral WAT from women pre-VSG. Six months of medical care increased p-ACC in SubQ WAT by 5-fold compared to baseline. IR displayed similar expression in the visceral compared to SubQ WAT in women pre-VSG. IR expression increased by 20-fold at 6-months of medical care compared to baseline in SubQ WAT. p-FOXO1 displayed similar expression in the visceral compared to SubQ WAT. However, p-FOXO1 was decreased at 6-months of medical care compared to baseline. p-AKT levels were similar in visceral compared to SubQ WAT pre-VSG. However, p-AKT levels were significantly increased by 4-fold at 6-months of medical care compared to baseline. CONCLUSION: None of the insulin signaling intermediates measured were different in visceral compared to SubQ in women with obesity and PCOS. Additionally, the findings indicated lowered DNL, lowered regulation of gluconeogenic genes and thus lowered gluconeogenesis, and increased insulin action in SubQ WAT in women with obesity and PCOS after 6-months of medical care. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m.
format Online
Article
Text
id pubmed-9624999
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96249992022-11-14 PSUN123 Increased Expression of Insulin Signaling Intermediates After Six-Months Of Medical Care In Women With Obesity And Polycystic Ovary Syndrome Akalestou, Elina Andrisse, Stanley Johnson, Brett Miras, Alexander Dimitri O’Donnell, Karen Samarasinghe, Suhaniya J Endocr Soc Adipose Tissue, Appetite, & Obesity BACKGROUND: Recently an androgen-induced obesity-independent mechanism of insulin resistance in a mouse model mimicking lean polycystic ovary syndrome (PCOS) was discovered. To date there is little to no data on the mechanism of insulin resistance or molecular insulin signaling in adipose tissue of women with PCOS undergoing Vertical Sleeve Gastrectomy (VSG). Does the mechanism of androgen receptor (AR)-mediated regulation of insulin signaling seen in the lean PCOS mouse model occur in adipose tissue of women with obesity and PCOS? OBJECTIVE: We hypothesize that in women with obesity and PCOS, those with higher levels of free androgen index will display more dysregulation in the insulin signaling pathway in adipose tissue. More specifically, we believe that visceral more than subcutaneous adipose tissue in the women in the study will display more dysregulation; and lastly that VSG will alleviate insulin signaling dysregulation. Briefly, insulin activates insulin receptor (IR) which leads to activation of phospho-AKT which increases phosphorylated forkhead box 01 (p-FOXO1, gluconeogenesis regulation) and transcriptionally regulates acetyl co-A carboxylase (ACC, de novo lipogenesis (DNL) regulation). METHODS: This is a nested mechanistic study within a randomised controlled clinical trial. We performed molecular analyses (Western blots for protein and qPRC for mRNA expression, respectively, n = 3-4/group) exploring intermediates in the insulin signaling pathway (IR, p-AKT, p-FOXO1, and ACC) in (i) visceral and subcutaneous (SubQ) adipose tissue from women with obesity and PCOS before VSG bariatric surgery (n = 3/group); and (ii) SubQ WAT from women with obesity and PCOS at baseline and six-months after medical intervention with metformin (MTF) and lifestyle modification. RESULTS: Subcutaneous (SubQ) white adipose tissue (WAT) displayed similar levels of p-ACC compared to visceral WAT from women pre-VSG. Six months of medical care increased p-ACC in SubQ WAT by 5-fold compared to baseline. IR displayed similar expression in the visceral compared to SubQ WAT in women pre-VSG. IR expression increased by 20-fold at 6-months of medical care compared to baseline in SubQ WAT. p-FOXO1 displayed similar expression in the visceral compared to SubQ WAT. However, p-FOXO1 was decreased at 6-months of medical care compared to baseline. p-AKT levels were similar in visceral compared to SubQ WAT pre-VSG. However, p-AKT levels were significantly increased by 4-fold at 6-months of medical care compared to baseline. CONCLUSION: None of the insulin signaling intermediates measured were different in visceral compared to SubQ in women with obesity and PCOS. Additionally, the findings indicated lowered DNL, lowered regulation of gluconeogenic genes and thus lowered gluconeogenesis, and increased insulin action in SubQ WAT in women with obesity and PCOS after 6-months of medical care. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m. Oxford University Press 2022-11-01 /pmc/articles/PMC9624999/ http://dx.doi.org/10.1210/jendso/bvac150.050 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Adipose Tissue, Appetite, & Obesity
Akalestou, Elina
Andrisse, Stanley
Johnson, Brett
Miras, Alexander Dimitri
O’Donnell, Karen
Samarasinghe, Suhaniya
PSUN123 Increased Expression of Insulin Signaling Intermediates After Six-Months Of Medical Care In Women With Obesity And Polycystic Ovary Syndrome
title PSUN123 Increased Expression of Insulin Signaling Intermediates After Six-Months Of Medical Care In Women With Obesity And Polycystic Ovary Syndrome
title_full PSUN123 Increased Expression of Insulin Signaling Intermediates After Six-Months Of Medical Care In Women With Obesity And Polycystic Ovary Syndrome
title_fullStr PSUN123 Increased Expression of Insulin Signaling Intermediates After Six-Months Of Medical Care In Women With Obesity And Polycystic Ovary Syndrome
title_full_unstemmed PSUN123 Increased Expression of Insulin Signaling Intermediates After Six-Months Of Medical Care In Women With Obesity And Polycystic Ovary Syndrome
title_short PSUN123 Increased Expression of Insulin Signaling Intermediates After Six-Months Of Medical Care In Women With Obesity And Polycystic Ovary Syndrome
title_sort psun123 increased expression of insulin signaling intermediates after six-months of medical care in women with obesity and polycystic ovary syndrome
topic Adipose Tissue, Appetite, & Obesity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624999/
http://dx.doi.org/10.1210/jendso/bvac150.050
work_keys_str_mv AT akalestouelina psun123increasedexpressionofinsulinsignalingintermediatesaftersixmonthsofmedicalcareinwomenwithobesityandpolycysticovarysyndrome
AT andrissestanley psun123increasedexpressionofinsulinsignalingintermediatesaftersixmonthsofmedicalcareinwomenwithobesityandpolycysticovarysyndrome
AT johnsonbrett psun123increasedexpressionofinsulinsignalingintermediatesaftersixmonthsofmedicalcareinwomenwithobesityandpolycysticovarysyndrome
AT mirasalexanderdimitri psun123increasedexpressionofinsulinsignalingintermediatesaftersixmonthsofmedicalcareinwomenwithobesityandpolycysticovarysyndrome
AT odonnellkaren psun123increasedexpressionofinsulinsignalingintermediatesaftersixmonthsofmedicalcareinwomenwithobesityandpolycysticovarysyndrome
AT samarasinghesuhaniya psun123increasedexpressionofinsulinsignalingintermediatesaftersixmonthsofmedicalcareinwomenwithobesityandpolycysticovarysyndrome